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Abstract. Gn-RH agonists or surgical castration are
considered standard treatment for patients affected by
metastatic prostate cancer. Despite greater cost, chemical
castration is often considered the treatment of choice as it is
psychologically better tolerated. We report our experience of
one patient undergoing treatment with Gn-RH agonist who
developed an early resistance to the administered drug, with
serum testosterone levels within the range of normality.
The effects of castration in prostate cancer treatment were
described by Huggins in 1940.
More recently, in the seventies, the introduction of LH-RH
agonists allowed the wide development in clinical practice of
chemical castration. This is more expensive, but
psychologically better tolerated. We report the case of one
patient presenting resistance to LH-RH agonists.
Case Report
A 76-year-old man with hormone-naïve bone metastatic
prostate cancer had shown ECOG performance status 0,
and initial PSA of 49.72 ng/ml in November 2003. Since
then, the patient underwent treatment with Flutamide 750
mg daily, triptorelin 11.25 mg every 3 months and
zoledronic acid 4 mg every 4 weeks. In January 2004, PSA
reached nadir level (6.1 ng/ml), whereas in March it
increased to 11.3 ng/ml with serum testosterone levels above
the range of castration (875 ng/dl).
Endocrine tests revealed FT3 (34.4 pmol/L), FT4 (13.6
pmol/L), TSH (0.6 mU/L), inibin-B (173 pg/ml), SHBG (60
nmol/L), prolactine (180 mlU/L), ACTH (46 ng/L), cortisol
(520 nmol/L), DHEA-S ( 8 mmol/L), SHBG ( 50 nmol/L),
androstenedion (8 nmol/L) and 17 OH progesterone (2.4
nmol/L), all within the ranges of normality.
Basal LH (6.8 mIU/mL), FSH (7.0 mIU/mL) and
testosterone (875 ng/ml) levels were normal. Oral
etinilestasradiol 1 mg was given, with significant reduction
of gonadotropin and serum testosterone levels; a further
test was performed with LH-RH antagonist (Cetrorelix 0.25
s.c.), showing again a significant decrease of gonadotropin
and serum testosterone levels.
Gn-RH antagonists are not available in Italy for
prostate cancer treatment; the patient was administered
leuprorelin 3.75 mg every 4 weeks. Bone scan and
abdomen CT scan were stable. Successive PSA was 32.65
ng/ml with castrate serum testosterone levels (< 50 ng/ml);
one month later, PSA was 41.65 ng/ml and the serum
testosterone reached normal levels. Following this, the
patient developed pain in the right lower limb, requiring
strong narcotics (morphine-based therapy) and a
worsening of ECOG performance status, with a PSA level
of 51.2 ng/ml. Bilateral orchiectomy was thus performed at
the end of June 2004. 
After the procedure, the patient became asymptomatic,
the PSA value decreased to 44 ng/ml and testosterone to
castrate levels.
Discussion
Recently, case reports regarding LH-RH agonists
resistance have been published (1,2) showing their
involvement in monitoring serum testosterone levels in
patients treated with these drugs. However, there is a lack
of evidence about risks factors or mechanisms of
resistance. In our case, the non testicular origin of serum
testosterone level, functional pathologies of the Hipophysis
or alteration of the LH-RH-Gonadotropins-testis pathway
have been excluded. 
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To our knowledge, this is the first time that the LH-
FSH pathway has been tested (using ethinylestradiol and
LH-RH antagonists), in a LH-RH agonist-resistant
hormone-naïve prostate cancer patient. It appears that
both ethinylestradiol and LH-RH antagonists effectively
inhibit testosterone production, albeit that further studies
are needed to confirm the therapeutic role of these drugs
in Gn-RH non-responders.
In these patients, the experimental use of LH-RH
antagonists might be studied before definitive orchiectomy
in order to reach stable castration levels of testosterone.
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